[18F]Tetrafluoroborate, a new natrium-iodide symporter (NIS) PET/CT radiopharmaceutical: an overview focused on differentiated thyroid cancer
Authors' conclusion
TFB is a promising tracer in relapsing DTC, showing higher sensitivity and less radiation exposure than the standard methods. The TFB and 18F-FDG combination appears particularly intriguing, especially when disease heterogeneity is suspected. However, data are still sparse and need to be confirmed by further investigations.
Study context
- Population
- Patients with differentiated thyroid cancer (DTC) (relapsing DTC)5 studies
- Comparison
- TFB PET/CT vs standard NIS imaging and 18F-FDG PET/CT
- Outcome
- TFB diagnostic performance (sensitivity) vs standard methods; biodistribution and dosimetry
Methodological detailsQUADAS-2 risk of bias assessment
- QUADAS-2 risk of bias assessment
Pooled result
As reported in the abstract
Diagnostic performance and dosimetry
- TFB performed better than 131I
- TFB + 18F-FDG PET/CT combination achieved the best sensitivity
- TFB delivered significantly less dose than the other NIS tracers
- 2 studies on biodistribution and dosimetry; 3 on diagnostic performance
Original publication
[18F]Tetrafluoroborate, a new NIS PET/CT radiopharmaceutical: an overview focused on differentiated thyroid cancer. Eur Thyroid J. Published 10 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →